ALBO News and Press, Albireo Pharma Inc. From 04/15/19

An open-label Phase 2 clinical trial evaluating Albireo Pharma's ( ALBO -3.9% ) lead candidate A4250 in pediatric Alagille syndrome and biliary atresia patients for the treatment of cholestasis (restricted or blocked bile flow) showed a positive effect . The results were presented at The ...

- Reduction in serum bile acids and pruritus observed in both populations –  - Alagille abstract selected for inclusion in ’Best of ILC’ –  - Albireo plans to initiate second A4250 pivotal program in biliary atresia second half of 2019 – ...

The FDA has cleared Albireo Pharma's (NASDAQ: ALBO ) IND application for a Phase 2 clinical trial of elobixibat, once-daily, orally-available ileal bile acid transporter (IBAT) inhibitor, for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)....

– Initiation of Phase 2 clinical trial expected in Q2 2019 –  – IBAT inhibition has potential to impact key markers of NASH – BOSTON, April 11, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver dise...

BOSTON, April 01, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April: H.C. Wainwrigh...

BOSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that results from its completed Phase 2 clinical trial of lead product candidate A4250 in children w...

-- Significant recent rare disease product launch and access experience -- -- Key addition as Albireo prepares for commercialization of A4250 -- BOSTON, March 21, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company dev...

Albireo Pharma, Inc. (ALBO) Q4 2018 Earnings Conference Call March 7, 2019 08:30 ET Company Participants Paul Arndt - Investor Relations Ron Cooper - President and Chief Executive Officer Patrick Horn - Chief Medical Officer Simon Harford - Chief Financial Officer Conference...

Albireo Pharma (NASDAQ: ALBO ): FY GAAP EPS of -$3.94. More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- A4250 Phase 3 PFIC pivotal program on target for end of ‘19/early ’20 topline readout - - Plan to initiate second A4250 pivotal program in biliary atresia - - Plan to initiate Phase 2 study with elobixibat in NASH - - Management to host conference call and webcast tod...